203 related articles for article (PubMed ID: 20847658)
1. Treatment of ocular graft-versus-host disease with topical cyclosporine 0.05%.
Malta JB; Soong HK; Shtein RM; Musch DC; Rhoades W; Sugar A; Mian SI
Cornea; 2010 Dec; 29(12):1392-6. PubMed ID: 20847658
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of topical cyclosporine 0.05% in the treatment of dry eye associated with graft versus host disease.
Rao SN; Rao RD
Cornea; 2006 Jul; 25(6):674-8. PubMed ID: 17077659
[TBL] [Abstract][Full Text] [Related]
3. Topical cyclosporine-A in dry eye associated with chronic graft versus host disease.
Kurt RA; Yalçindag N; Atilla H; Arat M
Ann Ophthalmol (Skokie); 2009; 41(3-4):166-9. PubMed ID: 20214049
[TBL] [Abstract][Full Text] [Related]
4. Ophthalmic cyclosporine use in ocular GVHD.
Lelli GJ; Musch DC; Gupta A; Farjo QA; Nairus TM; Mian SI
Cornea; 2006 Jul; 25(6):635-8. PubMed ID: 17077652
[TBL] [Abstract][Full Text] [Related]
5. [A 0,05% cyclosporine treatment of the advanced dry eye syndrome].
Kujawa A; Rózycki R
Klin Oczna; 2005; 107(4-6):280-6. PubMed ID: 16118939
[TBL] [Abstract][Full Text] [Related]
6. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy.
Toker E; Asfuroğlu E
Cornea; 2010 Feb; 29(2):133-40. PubMed ID: 19966564
[TBL] [Abstract][Full Text] [Related]
7. The effect of decreasing the dosage of cyclosporine A 0.05% on dry eye disease after 1 year of twice-daily therapy.
Su MY; Perry HD; Barsam A; Perry AR; Donnenfeld ED; Wittpenn JR; D'Aversa G
Cornea; 2011 Oct; 30(10):1098-104. PubMed ID: 21407074
[TBL] [Abstract][Full Text] [Related]
8. Prospective Randomized Trial Comparing Efficacy of Topical Loteprednol Etabonate 0.5% Versus Cyclosporine-A 0.05% for Treatment of Dry Eye Syndrome Following Hematopoietic Stem Cell Transplantation.
Boynton GE; Raoof D; Niziol LM; Hussain M; Mian SI
Cornea; 2015 Jul; 34(7):725-32. PubMed ID: 25850708
[TBL] [Abstract][Full Text] [Related]
9. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment.
Wilson SE; Perry HD
Ophthalmology; 2007 Jan; 114(1):76-9. PubMed ID: 17070588
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of topical cyclosporine for the treatment of dry eye disease.
Perry HD; Solomon R; Donnenfeld ED; Perry AR; Wittpenn JR; Greenman HE; Savage HE
Arch Ophthalmol; 2008 Aug; 126(8):1046-50. PubMed ID: 18695097
[TBL] [Abstract][Full Text] [Related]
11. Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease.
Wang Y; Ogawa Y; Dogru M; Kawai M; Tatematsu Y; Uchino M; Okada N; Igarashi A; Kujira A; Fujishima H; Okamoto S; Shimazaki J; Tsubota K
Bone Marrow Transplant; 2008 Feb; 41(3):293-302. PubMed ID: 17982500
[TBL] [Abstract][Full Text] [Related]
12. The effect of topical cyclosporine A on clinical findings and cytological grade of the disease in patients with dry eye.
Sahli E; Hoşal BM; Zilelioğlu G; Gülbahçe R; Ustün H
Cornea; 2010 Dec; 29(12):1412-6. PubMed ID: 20847673
[TBL] [Abstract][Full Text] [Related]
13. Effects of topical cyclosporine a plus artificial tears versus artificial tears treatment on conjunctival goblet cell density in dysfunctional tear syndrome.
Demiryay E; Yaylali V; Cetin EN; Yildirim C
Eye Contact Lens; 2011 Sep; 37(5):312-5. PubMed ID: 21792057
[TBL] [Abstract][Full Text] [Related]
14. Long-term clinical course of dry eye in patients with chronic graft-versus-host disease referred for eye examination.
Sáles CS; Johnston LJ; Ta CN
Cornea; 2011 Feb; 30(2):143-9. PubMed ID: 20885310
[TBL] [Abstract][Full Text] [Related]
15. [Corneal complications after hematopoietic stem cell transplantation].
Mittelviefhaus H; Auw-Hädrich C
Ophthalmologe; 2003 Mar; 100(3):222-9. PubMed ID: 12640552
[TBL] [Abstract][Full Text] [Related]
16. The use of topical cyclosporin A in ocular graft-versus-host-disease.
Kiang E; Tesavibul N; Yee R; Kellaway J; Przepiorka D
Bone Marrow Transplant; 1998 Jul; 22(2):147-51. PubMed ID: 9707022
[TBL] [Abstract][Full Text] [Related]
17. Ocular Findings of Pediatric Dry Eye Related to Graft-Versus-Host Disease.
Bingöl Kızıltunç P; Büyüktepe TÇ; Yalçındağ FN; Ertem M; İnce E; İleri T; Atilla H
Turk J Ophthalmol; 2021 Jun; 51(3):134-138. PubMed ID: 34187145
[TBL] [Abstract][Full Text] [Related]
18. Early (day -7) versus conventional (day -1) inception of cyclosporine-A for graft-versus-host disease prophylaxis after unrelated donor hematopoietic stem cell transplantation in children. Long-term results of an AIEOP prospective, randomized study.
Lanino E; Rondelli R; Locatelli F; Messina C; Pession A; Balduzzi A; Favre C; Santarone S; Rabusin M; Pollichieni S; Cesaro S; Dini G;
Biol Blood Marrow Transplant; 2009 Jun; 15(6):741-8. PubMed ID: 19450759
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileusis.
Salib GM; McDonald MB; Smolek M
J Cataract Refract Surg; 2006 May; 32(5):772-8. PubMed ID: 16765793
[TBL] [Abstract][Full Text] [Related]
20. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis.
Byrne JL; Stainer C; Hyde H; Miflin G; Haynes AP; Bessell EM; Russell NH
Bone Marrow Transplant; 1998 Sep; 22(6):541-5. PubMed ID: 9758340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]